In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents

Anti-Cancer Drugs

Volumn 11, Issue 2, 2000, Pages 93-99

  Ollikainen, Tiina ^a   Knuuttila, Aija ^b   Suhonen, Satu ^a   Taavitsainen, Matti ^b   Jekunen, Antti ^c   Mattson, Karin ^b   Linnainmaa, Kaija ^a  

^a FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c Rhone Poulenc Rorer Finland Ltd   (Finland)

Author keywords

Comet assay; Docetaxe; Gemcitabine; In vitro sensitivity; Melsothelioma; Paclitaxel; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; DOCETAXEL; GEMCITABINE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL KILLING; CELL VIABILITY; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MESOTHELIOMA; MESOTHELIUM CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TRANSFORMED; CELL SURVIVAL; COMET ASSAY; DEOXYCYTIDINE; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; EPITHELIAL CELLS; HUMANS; MESOTHELIOMA; PACLITAXEL; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 0034077312     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200002000-00005     Document Type: Article

References (19)

1. McDonald AD, McDonald JC. Epidemiology of malignant mesothelioma. In: Antman K, Aisner J, eds. Asbestos-related Malignancy. Orlando, FL: Grune Stratton 1987: 57-79.
2. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 1998; 113: S66-73.
3. Sugarbaker DJ, Jaklitsch MT, Liptay M. Mesothelioma and radical multimodality therapy: Who benefits? Chest 1995; 107: S345-50.
4. Hand A, Pelin K, Mattson K, Linnainmaa K. Interferon (IFN)-α and IFN-γ in combination with methotrexate: In vitro sensitivity studies in four human mesothelioma cell lines. Anti-Cancer Drugs 1995; 6: 77-82.
5. Solheim Ø.P, Sæter G, Finnanger AM, Stenwig AE. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992; 65: 956-60.
6. Halme M, Knuuttila A, Vehmas T, et al. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br J Cancer 1999; 80: 1781-5.
7. Pelin-Enlund K, Husgafvel-Pursiainen K, Tammilehto L, et al. Asbestos-related malignant mesothelioma: Growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients. Carcinogenesis 1990; 11: 673-81.
8. Ke Y, Reddel RR, Gerwin BI, et al. Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am Pathol 1989; 134: 979-91.
9. Pelin K, Husgafvel-Pursiainen K, Vallas M, Vanhala E, Linnainmaa K. Cytotoxicity and anaphase aberrations induced by mineral fibers in cultured human mesothelial cells. Toxic in Vitro 1992, 6: 445-50.
10. Sing NP, Tice RR, Stephens RE, Schneider EL. A microgel electrophoresis technique for the direct quantitation of DNA damage and repair in individual fibroblasts cultured on microscope slides. Mutat Res 1991; 252: 289-96.
11. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 288-91.
12. Gueritte-Voegelein F, Guenard D, Lavelle F, Le-Goff MT, Mangatal L, Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991; 34: 992-8.
13. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced RP 56976 and palitaxel: Reversibility, ligand stoichiometry and competition. Biochemistry 1993; 32: 2747-55.
14. Hanauske A-R, Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DD. Effects of taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anti-Cancer Drugs 1992; 3: 121-4.
15. Hsiang Y, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-82.
16. Kaneda N, Nagata H, Furuta T, Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990; 50: 1715-20.
17. Ruiz-Van Haperen VW, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ. Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 1994; 48: 1327-39.
18. Fairbairn DW, Olive PL, O'Neill KL. The comet assay: A comprehensive review. Mutat Res 1995; 339: 37-59.
19. Collins AR, Dobson VL, Duinska M, Kennedy G, Têtina R. The comet assay: What can it really tell us? Mutat Res 1997; 375: 183-93.